Please assess the completion status of the following clinical trial:

Trial Title: Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 15.0

Eligibility Criteria:
Part A SAD:~Inclusion Criteria:~* Male or female age 18 - 55~* BMI 18 - 32 kg/m\^2~Exclusion Criteria:~* Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation~* History or evidence of drug or alcohol abuse~* History of intolerance to SC injection~Parts B/C MAD:~Inclusion Criteria:~* Male or female age 18 - 65~* BMI 18 - 32 kg/m\^2~* Chronic HBV infection for \>/= 6 months~Exclusion Criteria:~* Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation~* Significant fibrosis or cirrhosis~* History or evidence of drug or alcohol abuse~* History of intolerance to SC injection~* History of chronic liver disease from any cause other than chronic HBV infection~* History of hepatic decompensation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Part A: SAD VIR-2218 50 mg (Type: EXPERIMENTAL): Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
- Part A: SAD VIR-2218 100 mg (Type: EXPERIMENTAL): Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
- Part A: SAD VIR-2218 200 mg (Type: EXPERIMENTAL): Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
- Part A: SAD VIR-2218 400 mg (Type: EXPERIMENTAL): Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
- Part A: SAD VIR-2218 600 mg (Type: EXPERIMENTAL): Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
- Part A: SAD VIR-2218 900 mg (Type: EXPERIMENTAL): Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
- Part A: SAD Placebo (Type: PLACEBO_COMPARATOR): Healthy subjects received a single dose of placebo administered SC
- Part B: MAD VIR-2218 20 mg (Type: EXPERIMENTAL): Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart.
- Part B: MAD VIR-2218 50 mg (Type: EXPERIMENTAL): Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
- Part B: MAD VIR-2218 100 mg (Type: EXPERIMENTAL): Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
- Part B: MAD VIR-2218 200 mg (Type: EXPERIMENTAL): Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
- Part C: MAD VIR-2218 50 mg (Type: EXPERIMENTAL): Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
- Part C: MAD VIR-2218 200 mg (Type: EXPERIMENTAL): Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
- Part B: MAD Placebo (Type: PLACEBO_COMPARATOR): Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
- Part C: MAD Placebo (Type: PLACEBO_COMPARATOR): Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete